BeaconEquity.com announces the publication of an article covering recent news from Allos Therapeutics (OTCBB: ALTH) expecting the FDA to release an approval decision for the drug pralatrexate for the treatment of relapsed or refractory PTCL.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m
In the article the author writes:
“Allos presented its phase II results of pralatrexate this past weekend at the American Society of Clinical Oncology (ACSO) annual meeting in Orlando, Fla. The U.S. Food and Drug Administration (FDA) is expected to release an approval decision by September 24. Presently, no drug to treat peripheral T-cell lymphoma (PTCL) has been approved by the FDA.”
According to Allos’ chief medical officer, Pralatrexate might be an effective treatment option for patients with relapsed or refractory PTCL:
“’PTCL is an extremely challenging disease, and one for which there are currently no FDA-approved therapies,’ commented Pablo J. Cagnoni, chief medical officer of Allos stated in the press release. ‘The data from the PROPEL study suggest that pralatrexate may be an effective treatment option for patients with relapsed or refractory PTCL, including those with the disease that has been unresponsive to prior therapy. Our NDA for this patient population has been accepted for priority review and we look forward to working with the FDA through the review process to bring this product to market.’”
To read the entire article visit http://www.beaconequity.com/m
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s market news is one of the fastest growing small-cap blogs in the investment community. Beacon is the authority on research in the small-cap sector, and our analysts strive each day to find the stocks poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas.
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
